Alopecia Treatment (Hair Loss) Market - Growth, Trends, and Forecast (2019 - 2024)

The Market is segmented by Disease Type, Drug Type (Minoxidil, Finasteride, and Others), Route of Administration, Gender, Distribution Channel and Geography

Market Snapshot

Alopecia Treatment (Hair Loss) Market 1 (1)
Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

5.2%

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

Alopecia is a term used to describe excessive hair damage under certain medical conditions or dietary issues. A sedentary lifestyle and unhealthy diets are leading to loss of hair among masses. Furthermore, aging and hormonal imbalance, increasing chronic disease like arthritis, cancer, hypertension, depression also leads to hair loss, especially among the middle aged population. According to the American Hair Loss Association, androgenetic alopecia accounts for over 95% of hair loss in men.  Over 800 thousand patients are seeking some kind of treatment for hair loss worldwide. For the treatment of alopecia, the US FDA approved two drugs - Minoxidil, to treat hypertension and finasteride (Propecia) to treat benign prostate hyperplasia (BPH). American Hair Loss Association recommends the use of minoxidil in patients who have not responded to finasteride treatment. Prevalence rate of alopecia is high among working age population.

In recent years, many novel drugs have been approved by the regulatory bodies for treatment of alopecia and many drugs are in pipeline, which are expected to receive approval in the near future. Concert Pharmaceuticals Inc. received fast track designation from the US Food and Drug Administration, (FDA) for its novel product for the treatment of moderate-to-severe alopecia areata in January 2018. During the same time, HCell Inc., a biotechnology company received orphan drug designation (ODD) for its product from FDA. In 2017, Perrigo Company PLC. Launched over-the-counter Women's Rogaine, which helps to regrow hair on top of the scalp. The launches of such novel products in the market is expected to drive the global alopecia treatment market growth in the near future.

Scope of the Report

As per the scope of the report, Alopecia Treatment (Hair Loss) are the drugs which are indicated for the treatment of alopecia. For instance, Minoxidil, Finasteride, and Cyclosporine.

By Disease Type
Androgenic Alopecia
Alopecia Areata
Ciatricial Alopecia
Traction Alopecia
Alopecia Totalis
By Drug Type
Minoxidil
Finasteride
Other Drug Types
By Route of Administration
Oral
Topical
Injectable
By Gender
Males
Females
By Distribution Channel
Hospitals
Retail Pharmacies
Online Pharmacies
Geography
North America
US
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Female is Expected to Hold Largest Share of Global Alopecia Treatment (Hair Loss) Market, Over the forecast period

About one-third of women experience hair loss (alopecia) at some time in their lives. Among postmenopausal women, as many as two-thirds suffer hair thinning or bald spots. Hair loss in women often has a greater impact than hair loss does on men, because it's less socially acceptable for them. Androgenetic alopecia is the most common cause of hair loss in women. Alopecia can severely affect a woman's emotional well-being and quality of life. Although Alopecia is more common in male than female, the female has the largest share in the market owing to the factors such as high awareness levels coupled with increased frequency of Polycystic Ovary Syndrome (PCOS) causing hormonal imbalance that leads to androgenetic alopecia.

Alopecia Treatment (Hair Loss) Market  (2)

To understand key trends, Download Sample Report

North America Region Holds the Largest Market Share of Alopecia Treatment (Hair Loss) Market

North America dominates the Alopecia Treatment (Hair Loss) market due to the presence of technologically advanced healthcare infrastructure, high disposable income, and availability of novel therapeutics options pertaining to the treatments. According to the U.S. National Library of Medicine,  Alopecia areata affects 1 in every 500 to 1,000 people in the United States. It is one of many recognized forms of alopecia, alopecia areata is the second most common form after androgenetic alopecia. Alopecia areata affects men and women equally, and it can occur in people of any ethnic background.

Therefore, the high prevalence and the proportionally high treatment rates pertaining to hair loss in the U.S. are high major drivers for the North American market.

Alopecia Treatment (Hair Loss) Market  (3)

To understand geography trends, Download Sample Report

Competitive Landscape

Some of the prominent industry players operating in total Alopecia Treatment (Hair Loss) market include Sun Pharmaceuticals Industries Ltd., Aclaris Therapeutics Inc., Cipla Inc., Concert Pharmaceuticals Inc., Daiichi Sankyo Inc. Development of advanced products for better outcomes and rigorous marketing is competitive strategies adopted by market players.

Major Players

  1. Sun Pharmaceuticals Industries Ltd.
  2. Merck & Co., Inc.
  3. Cipla Inc.
  4. Concert Pharmaceuticals Inc.
  5. Johnson & Johnson AG

* Complete list of players covered available in the table of contents below

Alopecia Treatment (Hair Loss) Market (4)

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Alopecia

      2. 4.2.2 Increasing R&D Initiatives and New Product Launches and Approvals

    3. 4.3 Market Restraints

      1. 4.3.1 Patent Expiry of Many Blockbuster Drugs

      2. 4.3.2 Side Effects Associated with the Available Hair Loss Treatment Therapies

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Disease Type

      1. 5.1.1 Androgenic Alopecia

      2. 5.1.2 Alopecia Areata

      3. 5.1.3 Ciatricial Alopecia

      4. 5.1.4 Traction Alopecia

      5. 5.1.5 Alopecia Totalis

    2. 5.2 By Drug Type

      1. 5.2.1 Minoxidil

      2. 5.2.2 Finasteride

      3. 5.2.3 Other Drug Types

    3. 5.3 By Route of Administration

      1. 5.3.1 Oral

      2. 5.3.2 Topical

      3. 5.3.3 Injectable

    4. 5.4 By Gender

      1. 5.4.1 Males

      2. 5.4.2 Females

    5. 5.5 By Distribution Channel

      1. 5.5.1 Hospitals

      2. 5.5.2 Retail Pharmacies

      3. 5.5.3 Online Pharmacies

    6. 5.6 Geography

      1. 5.6.1 North America

        1. 5.6.1.1 US

        2. 5.6.1.2 Canada

        3. 5.6.1.3 Mexico

      2. 5.6.2 Europe

        1. 5.6.2.1 Germany

        2. 5.6.2.2 UK

        3. 5.6.2.3 France

        4. 5.6.2.4 Italy

        5. 5.6.2.5 Spain

        6. 5.6.2.6 Rest of Europe

      3. 5.6.3 Asia Pacific

        1. 5.6.3.1 China

        2. 5.6.3.2 Japan

        3. 5.6.3.3 India

        4. 5.6.3.4 Australia

        5. 5.6.3.5 South Korea

        6. 5.6.3.6 Rest of Asia-Pacific

      4. 5.6.4 Middle East and Africa

        1. 5.6.4.1 GCC

        2. 5.6.4.2 South Africa

        3. 5.6.4.3 Rest of Middle East and Africa

      5. 5.6.5 South America

        1. 5.6.5.1 Brazil

        2. 5.6.5.2 Argentina

        3. 5.6.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Sun Pharmaceuticals Industries Ltd.

      2. 6.1.2 Aclaris Therapeutics Inc.

      3. 6.1.3 Cipla Inc.

      4. 6.1.4 Concert Pharmaceuticals Inc.

      5. 6.1.5 Daiichi Sankyo Inc.

      6. 6.1.6 GlaxoSmithKline PLC.

      7. 6.1.7 HCell Inc.

      8. 6.1.8 Histogen Inc.

      9. 6.1.9 Merck & Co., Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information